Policy

Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC

May 18th 2021

The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.

House Committee Issues Blistering Report on AbbVie's Humira Tactics

May 18th 2021

By Tony Hagen

The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.

German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention

May 17th 2021

By Tony Hagen

Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).

US, EU Regulators Discuss Tailoring Biosimilar Approvals

May 10th 2021

By Tony Hagen

During a talk at the Medicines for Europe Biosimilar Medicines Conference, US and EU regulators discuss the potential for tailored approach to bring biosimilars to market sooner with less expense and wasted effort.

Regulators Look Back on 15 Years of Biosimilars in Europe

May 7th 2021

By Tony Hagen

Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.

The Difference Between an Interchangeable Biosimilar and One That Isn't

May 5th 2021

By Tony Hagen

The anatomy of an interchangeability switching study.

Amgen Canada Launches Adalimumab Biosimilar

May 4th 2021

Amgevita is now broadly available across Canada.

Biosimilar Business Roundup for April 2021

May 4th 2021

By Skylar Jeremias

Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.

AbbVie CEO Is on Deck as Antitrust Hearings Heat Up

May 3rd 2021

By Tony Hagen

Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.

Toothful or Toothless? Biden's Biosimilar Bills Under the Microscope

April 28th 2021

By Tony Hagen

How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.